LOS ANGELES–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24INVVY&src=ctag” target=”_blank”gt;$INVVYlt;/agt; lt;a href=”https://twitter.com/hashtag/CLASSACTION?src=hash” target=”_blank”gt;#CLASSACTIONlt;/agt;–Glancy
Prongay & Murray LLP (“GPM”), a national investors rights law
firm, announces that a class action lawsuit has been filed on behalf of
investors that acquired Indivior PLC (“Indivior” or the “Company”) (OTC: INVVY)
securities between March 10, 2015 and April 9, 2019, inclusive
(the “Class Period”). Indivior investors have until June 24,
2019 to file a lead plaintiff motion.

If you are a shareholder who suffered a loss, click here
to participate.

If you wish to learn more about this action, or if you have any
questions concerning this announcement or your rights or interests with
respect to these matters, please contact Lesley Portnoy, Esquire, at
310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected],
or visit our website at www.glancylaw.com.

On April 9, 2019, the U.S. Department of Justice (“DOJ”) announced that
a federal grand jury had indicted Indivior “for engaging in an illicit
nationwide scheme to increase prescriptions of Suboxone Film, an opioid
drug used in the treatment of opioid addiction.” According to the
indictment, Indivior deceived “health care providers and health care
benefit programs into believing that Suboxone Film was safer, less
divertible, and less abusable than other opioid-addiction treatment
drugs,” acquiring billions of dollars in revenue in Suboxone Film
prescriptions.

On this news, the Company’s share price fell $4.48 per share, more than
66%, to close at $2.30 per share on April 10, 2019, on unusually heavy
trading volume.

The complaint filed in this class action alleges that throughout the
Class Period, Defendants made materially false and/or misleading
statements, as well as failed to disclose material adverse facts about
the Company’s business, operations, and prospects. Specifically,
Defendants failed to disclose to investors: (1) Indivior and its
executives engaged in an illicit nationwide scheme to increase
prescriptions of Suboxone Film; (2) Indivior illegally obtained billions
of dollars in revenue from Suboxone Film prescriptions by deceiving
health care providers and health care benefit programs; (3) as a result,
Indivior would face felony charges; and (4) due to the foregoing,
defendants’ statements about its business, operations, and prospects,
were materially false and misleading and/or lacked a reasonable basis at
all relevant times.

Follow us for updates on Twitter: twitter.com/GPM_LLP.

If you purchased shares of Indivior during the Class Period you may move
the Court no later than June 24, 2019 to ask the Court
to appoint you as lead plaintiff. To be a member of the Class you need
not take any action at this time; you may retain counsel of your choice
or take no action and remain an absent member of the Class. If you wish
to learn more about this action, or if you have any questions concerning
this announcement or your rights or interests with respect to these
matters, please contact Lesley Portnoy, Esquire, of GPM, 1925 Century
Park East, Suite 2100, Los Angeles California 90067 at 310-201-9150,
Toll-Free at 888-773-9224, by email to [email protected],
or visit our website at www.glancylaw.com.
If you inquire by email please include your mailing address, telephone
number and number of shares purchased.

This press release may be considered Attorney Advertising in some
jurisdictions under the applicable law and ethical rules.

Contacts

Glancy Prongay & Murray LLP, Los Angeles
Lesley Portnoy,
310-201-9150 or 888-773-9224
www.glancylaw.com
[email protected]